Arbutus Biopharma Corp
ABUS | NASDAQ
$5
-$0.01 (-0.20%)
At close: Sep 21, 2026, 4:00 PM ET
$5.03
+$0.03 (+0.54%)
After-hours:
Sep 21, 2026, 7:53 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 14.08M | 6.17M | 18.14M | 39.02M | 10.99M | 6.91M |
Cost of Revenue | 363K | n/a | n/a | n/a | n/a | 47.48M |
Gross Profit | 13.72M | 6.17M | 18.14M | 39.02M | 10.99M | -40.57M |
Operating Income | -27.05M | -76.32M | -78.1M | -65.46M | -73.52M | -57.81M |
Interest Income | 4.07M | 6.59M | 5.69M | 2.19M | 127K | 741K |
Pretax Income | -33.5M | -69.92M | -72.85M | -65.01M | -76.25M | -63.75M |
Net Income | -33.5M | -69.92M | -72.85M | -69.46M | -76.25M | -63.75M |
Selling & General & Admin | 15.89M | 22.11M | 22.48M | 17.83M | 17.14M | 14.85M |
Research & Development | 25.24M | 54.04M | 73.7M | 84.41M | 65.5M | 49.34M |
Other Expenses | -363K | 6.35M | 69K | 2.23M | 1.87M | -46.94M |
Operating Expenses | 40.77M | 82.49M | 96.24M | 104.48M | 84.51M | 17.24M |
Interest Expense | 97K | 137K | 459K | 1.73M | 2.86M | 4.01M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 41.13M | 82.49M | 96.24M | 104.48M | 84.51M | 64.72M |
Income Tax Expense | n/a | n/a | n/a | 4.44M | n/a | n/a |
Shares Outstanding (Basic) | 191.6M | 185.61M | 165.96M | 150.94M | 106.24M | 75.84M |
Shares Outstanding (Diluted) | 191.6M | 185.61M | 165.96M | 150.94M | 106.24M | 75.84M |
EPS (Basic) | -0.17 | -0.38 | -0.44 | -0.46 | -0.73 | -0.86 |
EPS (Diluted) | -0.17 | -0.38 | -0.44 | -0.46 | -0.73 | -0.86 |
EBITDA | -33.04M | -68.4M | -70.99M | -61.86M | -71.64M | -57.76M |
EBIT | -33.4M | -69.78M | -72.39M | -63.29M | -73.39M | -59.73M |
Depreciation & Amortization | 363K | 1.38M | 1.4M | 1.43M | 1.75M | 1.98M |
Add to Watchlist
Select watchlists to add or remove ABUS